MRK
US EQUITY
Health Care
Pharmaceuticals
CIK: 310158
Merck & Co. (MRK) Quant Factor Diagnostic & Fair Value Model
Merck & Co. (Ticker: MRK) is listed in the Health Care sector (Pharmaceuticals). Below is its point-in-time financial profile, valuation multiples, and cross-sectional factor diagnostics.
$145.27
-1.34%
Latest Close (2026-10-23)
Market Cap: $358.41B
P/E Ratio: 116.2
Momentum Strength
3M / 12M
+11.10%
1M: -1.83%
12M: +65.81%
Quality (ROE)
Point-in-Time
-5.23%
Trailing Return on Equity
Technical Trend
RSI 14
59.0
SMA50: $146.64
SMA200: $125.86
Valuation Multiplier
Trailing
116.2
Premium Multiple (> 30x P/E)
📊
Valuation & Multi-Factor Diagnostic
Premium Multiple (> 30x P/E)
MRK trades at 116.2x P/E, reflecting market-implied growth expectations for forward revenue and cash flow.
⚡
Benchmark Factor Strategy
S&P 500 Momentum Alpha Strategy
This strategy applies cross-sectional momentum and quality factor filters across large-cap US equities.
📈 Daily Candlestick & Volume Quant Chart
Interactive lightweight price action & volume breakdown over recent 90 trading days.
均线多头 (MA20/50)
Piotroski F-Score: 4/9 (Moderate Financial Health)
Official Point-in-Time Financial Filing History
Zero Lookahead Bias: Every financial metric is timestamped at the exact moment officially published to the market.
备案 CIK: 310158 · 10-K 年报 / 10-Q 季报
| Form | Period End | Filing Timestamp (Point-in-Time) | Revenue | Net Income | Operating CF | EPS (Diluted) |
|---|---|---|---|---|---|---|
| 10-Q | 2026-06-30 | 2026-08-07 | $16.61B | -$1.33B | $9.29B | $-0.54 |
| 10-Q | 2025-12-31 | 2026-08-07 | - | - | - | - |
| 10-Q | 2025-06-30 | 2026-08-07 | $15.81B | $4.43B | $5.79B | $1.76 |
| 10-Q | 2026-03-31 | 2026-05-04 | $16.29B | -$4.24B | $3.92B | $-1.72 |
| 10-Q | 2025-03-31 | 2026-05-04 | $15.53B | $5.08B | $2.50B | $2.01 |
| 10-K | 2025-12-31 | 2026-02-24 | $65.01B | $18.25B | $16.47B | $7.28 |
| 10-K | 2024-12-31 | 2026-02-24 | $64.17B | $17.12B | $21.47B | $6.74 |
| 10-K | 2023-12-31 | 2026-02-24 | $60.12B | $365.00M | $13.01B | $0.14 |
💡 Methodology & Frequently Asked Questions
Key reference details regarding Merck & Co. (MRK) valuation multiples, momentum factors, and point-in-time filing conventions.
How should MRK's current valuation multiple be interpreted? ↓
MRK trades at a trailing P/E of 116.2x within the Health Care sector (premium multiple (> 30x p/e)). Valuation multiples are computed using trailing-twelve-month GAAP earnings against the latest close price.
What are MRK's key momentum and technical factor indicators? ↓
As of the latest close, MRK shows a 1-month return of -1.83%, 3-month return of +11.10%, and 12-month return of +65.81%, with a 14-day RSI of 59.0. Momentum factors reflect short- and intermediate-term price velocity across the equity cross-section.
What is Point-in-Time (PIT) financial data and why does it matter for MRK? ↓
Point-in-Time indexing aligns corporate fundamentals with their official public filing timestamps (Form 10-Q/10-K) rather than accounting period-end dates. This methodology eliminates lookahead bias in historical equity backtests.
How can MRK be incorporated into systematic factor models? ↓
MRK can be evaluated within customized multi-factor models or screened against cross-sectional filters (such as momentum quintiles and return on equity) to analyze historical turnover and risk-adjusted return.